Literature DB >> 21741850

Improved detection and measurement of low levels of [18F]fluoride metabolized from [18F]-labeled pyrimidine nucleoside analogues in biological samples.

Vincenzo Paolillo1, Hsin Hsien Yeh, Uday Mukhopadhyay, Juri G Gelovani, Mian M Alauddin.   

Abstract

INTRODUCTION: It is important to identify all circulating metabolites, including free fluoride, for accurate pharmacokinetic modeling of [(18)F]-labeled radiotracers. We sought to determine the most efficient method to detect and quantify low levels of free [(18)F]fluoride in biological samples.
METHODS: Low levels of [(18)F]fluoride were analyzed using two methods: (A) an ion-exchange cartridge and gamma counting, and (B) radio-HPLC, to compare the detection limits of these two analytical methods. Twenty microliters of [(18)F]fluoride solution was loaded onto an ion-exchange cartridge, then eluted with 20% MeCN/water (5 ml) and radioactivity trapped in the cartridge counted on a gamma counter. [(18)F]Fluoride was also determined in plasma and urine from mice injected with [(18)F]-labeled thymidine analogues using Method A.
RESULTS: The detection sensitivity of Method A was 9.4-fold higher than that of Method B (0.075±0.004 vs. 0.71±0.02 nCi). With Method A, [(18)F]fluoride was determined in plasma for [(18)F]FLT, [(18)F]FMAU, [(18)F]FEAU and N(3)-[(18)F]FPrT as 1.4±0.31% (n=4), 0.17±0.49% (n=3), 4.88±1.62% (n=3) and 12.94±0.48% (n=4), respectively. The amount of [(18)F]fluoride determined in the urine was 11.49±1.60% (n=4) from [(18)F]FLT, 5.36±2.34% (n=3) from [(18)F]FMAU, 13.57±1.96% (n=3) from [(18)F]FEAU and 11.19±1.98% (n=4) from N(3)-[(18)F]FPrT.
CONCLUSION: Low levels of [(18)F]fluoride in biological samples can be detected and quantified using an ion-exchange cartridge and gamma counting. This methodology is simple, accurate and superior to the standard use of radio-HPLC on a C(18) column for metabolite analysis, and it should be useful in pharmacokinetic modeling for animal imaging studies using an [(18)F]-labeled radiotracer and PET.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21741850      PMCID: PMC3230730          DOI: 10.1016/j.nucmedbio.2011.05.008

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  18 in total

1.  Metabolite analysis of [11C]flumazenil in human plasma: assessment as the standardized value for quantitative PET studies.

Authors:  K Ishiwata; T Itou; M Ohyama; T Yamada; M Mishina; K Ishii; T Nariai; T Sasaki; K Oda; H Toyama; M Senda
Journal:  Ann Nucl Med       Date:  1998-02       Impact factor: 2.668

2.  Analysis of plasma metabolites during human PET-studies with three receptor ligands, [11C]YM-09151-2, [11C]doxepin and [11C]pyrilamine.

Authors:  K Ishiwata; K Yanai; R Iwata; T Takahashi; J Hatazawa; M Itoh; K Watabe; T Watanabe; T Ido
Journal:  Tohoku J Exp Med       Date:  1996-02       Impact factor: 1.848

3.  A new precursor for the radiosynthesis of [18F]FLT.

Authors:  S J Martin; J A Eisenbarth; U Wagner-Utermann; W Mier; M Henze; H Pritzkow; U Haberkorn; M Eisenhut
Journal:  Nucl Med Biol       Date:  2002-02       Impact factor: 2.408

4.  Gas chromatographic method for the determination of fluoride ion in biological samples. II. Stability of fluorine-containing drugs and compounds in human plasma.

Authors:  R Ikenishi; T Kitagawa
Journal:  Chem Pharm Bull (Tokyo)       Date:  1988-02       Impact factor: 1.645

5.  Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT.

Authors:  Hsin Hsien Yeh; Kazuma Ogawa; Julius Balatoni; Uday Mukhapadhyay; Asutosh Pal; Carlos Gonzalez-Lepera; Aleksandr Shavrin; Suren Soghomonyan; Leo Flores; Daniel Young; Andrei Y Volgin; Amer M Najjar; Victor Krasnykh; William Tong; Mian M Alauddin; Juri G Gelovani
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-10       Impact factor: 11.205

6.  Imaging DNA synthesis in vivo with 18F-FMAU and PET.

Authors:  Haihao Sun; Thomas J Mangner; Jerry M Collins; Otto Muzik; Kirk Douglas; Anthony F Shields
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

Review 7.  18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma.

Authors:  Lale Kostakoglu; Stanley J Goldsmith
Journal:  J Nucl Med       Date:  2003-02       Impact factor: 10.057

8.  N(3)-Substituted thymidine analogues V: synthesis and preliminary PET imaging of N(3)-[(18)F]fluoroethyl thymidine and N(3)-[(18)F]fluoropropyl thymidine.

Authors:  Uday Mukhopadhyay; Suren Soghomonyan; Hsin Hsien Yeh; Leo G Flores; Aleksandr Shavrin; Andrei Y Volgin; Juri G Gelovani; Mian M Alauddin
Journal:  Nucl Med Biol       Date:  2008-08       Impact factor: 2.408

Review 9.  Positron emission tomography for the diagnosis of breast cancer.

Authors:  C Rosé; J Dose; N Avril
Journal:  Nucl Med Commun       Date:  2002-07       Impact factor: 1.690

10.  Kinetics of 3'-deoxy-3'-[F-18]fluorothymidine uptake and retention in dogs.

Authors:  Anthony F Shields; John R Grierson; Otto Muzik; Joseph C Stayanoff; Jawana M Lawhorn-Crews; Joyce E Obradovich; Thomas J Mangner
Journal:  Mol Imaging Biol       Date:  2002-01       Impact factor: 3.488

View more
  2 in total

1.  Optimization of precursor synthesis, formulation and stability of 1'-[18F]fluoroethyl-β-D-lactose ([18F]FEL) for preclinical studies in detection of pancreatic cancer.

Authors:  Vincenzo Paolillo; Louis De Palatis; Mian M Alauddin
Journal:  Nucl Med Biol       Date:  2014-01-10       Impact factor: 2.408

Review 2.  Current opportunities and challenges of magnetic resonance spectroscopy, positron emission tomography, and mass spectrometry imaging for mapping cancer metabolism in vivo.

Authors:  Gigin Lin; Yuen-Li Chung
Journal:  Biomed Res Int       Date:  2014-03-03       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.